Imatinib and Nilotinib: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Coadministration increases exposure to both kinase inhibitors through a pharmacokinetic interaction.
Clinical significance and safety
A clinical study in TASIGNA labeling found increased exposure to both nilotinib and imatinib during coadministration. This finding is an interaction warning, not evidence that combining these cancer medicines is appropriate. Any overlap or switch must be managed by the oncology team.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.